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A novel series of benzopyran-3-carboxamide derivatives have been designed and synthesized using a smooth and linear 
multistep synthesis. Amidation of coumarin-3-carboxylic acid with glycine ethyl ester in the presence of EDC.HCl and 
HOBt as coupling agent followed by the hydrolysis results in the formation of key synthon, [(2-oxo-2H-1-benzopyran-3-
carbonyl) amino] acetic acid 7 which i                                                                              
                                         8(a-h). The synthesized compounds have been screened for their in vitro 
antibacterial and antioxidant activity and the results are expressed as MIC and IC50 values respectively. Further, the binding 
ability of synthesized compounds with different proteins have been examined by molecular docking studies. 
Keywords: EDC.HCl, HOBt, carboxamide, HATU, diisopropylamine, molecular docking 
Coumarin and their derivatives were considered to be 
an elite class of compounds because of their potential 
beneficial effects on human health
1
. Among numerous 
classes of biologically potent chemical moieties, 
coumarin derivatives are recognized as key building 
blocks in drug research. The synthesis of heterocyclic 
compounds containing coumarin moiety has attracted 
the attention of organic and medicinal chemist as 
members of this family exhibits wide spectrum of 
biological activities such as anticancer
2
, anti-oxidant
3
, 
analgesic
4
, antihistamine
5
, anti-HIV
6
, anti-coagulant
7
, 
antibacterial
8
, anti-inflammatory
9
, and antituberculosis
10
 
and enzyme inhibitors
11
. Apart from its medicinal 
applications, coumarins have widely used in food and 
cosmetics industries
12, fl                                
sensors
13
 and photosensitizers
14
. 
Coumarins, a class of benzopyrone family
15
 
constitutes one of the largest and most widespread 
classes in the realm of the plant as secondary metabolites 
and have important effects in plant biochemistry like 
control of respiration, photosynthesis, involved in the 
actions of plant growth hormones
16
. A large number of 
natural products containing coumarin nucleus as a 
structural core is extensively used  important scaffolds in 
medicinal and agricultural chemistry. For examples, 
Warfarin and Acenocoumarol are anticoagulant agents, 
7-hydroxycoumarin also known as umbelliferone used 
as            ,   fl                    ,           
indicator
17
, Osthole, a natural o-methylated coumarin 
shows antifungal activity
18
. 
A variety of methods have been documented for 
the synthesis of coumarins which can be further 
exploited as the molecular template for the synthesis  
of pharmocogicaly active heterocyclic compounds.  
The substitution at C-3 and C-4 position of the 
coumarin nucleus offers a high degree of diversity 
and useful for the development of new therapeutic 
agents. Several compounds with high insecticidal 
activity have been obtained by the modification of the 
amide bridge part as linker of two aryl rings. Sub 
structures of the acetamido group found in many 
insecticides have received considerable attention  
in pesticide and medicinal chemistry
19
. Ghaneiand  
co-workers reported the potency of coumarin-
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carboxamide derivatives bearing indole amine 
scaffold as new cholinesterase (AChE) inhibitors
20
. 
Coumarin and 3-carboxamide coumarin derivatives 
were described as FXIIa inhibitors
21
. Hao Liu and  
co-workers well documented the antimicrobial 
activity and Inhibitory effects against Topo II and 
Topo IV by introducing the pyrazole ring and binding 
it to coumarin with an amide bond to get novel set  
of carboxamide derivatives
22
. On the basis of SAR 
studies, Franco Chimenti and his co-workers pointed 
out that carboxamide functionality on the coumarin 
nucleus displayed a good anti-inflammatory effect in 
H. pylori-induced gastric inflammation
23
. 
Enlightened by the aforementioned remarkable  
and synthetic applications, we presented herein  
our research findings on development of efficient 
methodology to facilitate the synthesis of novel 
(benzylamino)-2-oxoethyl]-2-oxo-2H-1-benzopyran-
3-carboxamide derivatives by the reaction of [(2-oxo-
2H-1-benzopyran-3-carbonyl) amino] acetic acid with 
substituted benzyl amines and the synthesized 
compounds have been evaluated for their different 
pharmacological activities. 
 
Result and Discussion 
 
Chemistry 
The synthetic pathway leading to the new 
carboxamide derivatives accessed in the present  
study have been described in Scheme I. The key 
intermediate, 2-oxo-2H-1-benzopyran-3-carboxylic 
acid (4) required for the synthesis of target compounds 
have been synthesized by the saponification of ethyl  
2-oxo-2H-1-benzopyran-3-carboxylate which was 
synthesized by the reported procedure
24
. 
The coupling of the carboxylic acid with amines 
for the formation of amide linkage is performed using 
different several efficient and selective catalysts such 
as DCC, HBTU, TPTU and PS-TBTU which satisfies 
the chemistry protocol. In order to attain optimum 
reaction conditions such as yield of product and 
reaction time, we have screened with several coupling 
reagents. To best of our knowledge, we found that 
amides can be obtained in good yield with a span of 
reaction time using EDC.HCl and HOBt. 
In the first step, ethyl [(2-oxo-2H-1-benzopyran-3-
carbonyl) amino] acetate (6) was obtained by the 
treatment of coumarin carboxylic acid (4) with 
glycine ethyl ester hydrochloride (5) in presence of 
EDC.HCl and HOBt at RT which was subsequently 
hydrolysed in presence of 10% NaOH to give the 
corresponding benzopyran-3-carbonyl) amino] acetic 
acid (7). The final step involves the reaction of 
compound 7 with substituted aromatic amines in the  
presence of N, N-diisopropylethylamine and HATU 
to furnish N-[2-(benzylamino)-2-oxoethyl]-2-oxo-2H-
1-benzopyran-3-carboxamide derivatives (8a-h). 
The structures of all newly synthesized compounds 
have been characterised by IR, 
1
H NMR, 
13
C NMR 
 
 
Scheme I — Synthesis of benzopyran-3-carboxamide derivatives 8a-h 
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and mass analysis. The spectral data have been 
included in experimental part.  
Postulated structures of synthesized ethyl [(2-oxo-
2H-1-benzopyran-3-carbonyl) amino] acetate 6 was 
confirmed by IR, 
1
H and 
13
C NMR, and mass 
analysis. The FTIR spectrum of compound 6 showed 
a broadband at 3314.37 cm
−1 
which confirms the –NH 
stretching vibration of the amide. Three other peaks 
were observed at 1757.43 cm
−1,
 1713.32 cm
−1 
and 
1637.17 cm
−1 
for carbonyl group of amide carbonyl, 
carbonyl lactone of coumarin and ester carbonyl 
stretching respectively. The 
1
H NMR spectrum of 
compound 6 contained a triplet with a chemical shift 
of 1.16-1.19 ppm range, which consistent with the 
ethyl ester, as well as a singlet with a chemical  
shift of 9.03 ppm which consistent with the protons of 
the amide group. The 
13
C NMR spectrum of the 
compound 6 contained a signal at 169.86 ppm which 
was consistent with the carbonyl carbon of the amide 
group. The mass analysis of compound 6 gave a 
molecular ion peak with an m/z value of 276.03 for 
(M+H) which was consistent with the molecular 
formula C14H13NO5.  
The structure of compound 7 was confirmed by IR, 
1
H NMR, 
13
C NMR, and mass analysis. The FTIR 
spectrum of compound 7 showed characteristic 
broadband at 3313.20 cm
−1 
which attributed to –NH 
stretching vibration of the amide. Three other peaks 
were observed at 1735.75 cm
−1
, 1711.80 cm
−1 
and 
1656.70 cm
−1
 for carbonyl group of amide carbonyl, 
coumarin carbonyl, and ester carbonyl respectively. 
The broad absorption band at 3642.91 cm
−1 
attributed 
to –OH stretching vibration of carboxylic group. The 
1
H NMR spectrum of 7 contained a singlet with 
chemical shift of 9.03 ppm, which consistent with the 
                          ,                  δ 12.83 
which consistent with the protons of the carboxylic 
group. The 
13
C NMR spectrum of the compound 7 
contained a signal at 171.24 ppm which was 
consistent with the carbonyl carbon of the carboxylic 
functional group. The mass analysis of compound 7 
gave a molecular ion peak with an m/z value of 
246.0018 (M-H) which was consistent with the 
molecular formula C12H9NO5. 
The structure of carboxamide derivatives (8a-h) 
was confirmed by IR, 
1
H NMR, 
13
C NMR, and mass 
analysis. The FTIR spectrum of compound 8b 
displayed two peaks at 3271.64 cm-
1 
and 3329.31 
cm
−1
 which were attributed to –NH stretch of amide 
group of both benzyl amide and glycine ester amide 
respectively. The 
1
H NMR spectrum of 8b showed a 
doublet with the chemical shift of 4.05-4.66 ppm 
range corresponds to protons of benzyl –CH2, another 
           δ 4.31-4.32 range, which consistent  
with the protons of glycine- CH2. The absence of 
carboxylic -OH proton of compound 7 in 
1
H NMR at 
12.83 ppm can be observed in the series 8 (a-h) and a 
singlet with a chemical shift of 8.54 ppm, which 
consistent with the protons of the benzyl amide -NH 
group indicates the formation of new amide bond. 
Another singlet with a chemical shift of 9.12 ppm 
which consistent with the protons of glycine amide -
NH group. The 
13
C NMR spectrum of the compound 
8b contained a signal at δ 168.65                  
with the carbonyl carbon of coumarin. The mass 
spectrum of compound 8b gave a molecular ion peak 
with an m/z value of 355.02 (M+H) which consistent 
with the molecular formula C19H15FNO4. 
 
Biological activity 
 
Antibacterial activity 
All the newly synthesized compounds were 
evaluated for in-vitro antibacterial activity against a 
gram-negative bacterium Klebsiella pneumonia and 
gram-positive bacterium Bacillus subtilistaking 
Tetracycline as a standard drug. The results have been 
summarized in Table I. From the results, it can be 
noted that all the synthesized compounds exhibited 
significant antibacterial activity against tested strains. 
To further quantify the antibacterial potency of  
the synthesized compounds 8(a-h), the MIC was 
determined using Microtitre plate assay and the 
results are as shown in Table II. The results of MIC of 
tested compounds reveals that compound 8h with –Br 
substitution on p-position is potent against Bacillus 
subtilisand Klebsiella pneumonia with MIC value of 
0.078 mg/mL, followed by 8e with –Cl substitution 
on 4-position of aryl group which exhibited activity 
with MIC value of 0.078 mg/mL and 0.156 mg/mL 
against Bacillus subtilis and Klebsiella pneumonia 
respectively. Further, the compounds 8c and 8g 
showed considerable potency towards the tested 
strains whereas 8a and 8d showed a low response. 
From this data, it is found that electron-withdrawing 
groups such as Br, F, Cl plays a key role in enhancing 
the potency of synthesized compounds against the 
tested pathogens. From the close observation of 
primary antibacterial screening, it is revealed that the 
structural and electronic parameters may have a 
greater impact on v             fi        
antimicrobial activity
25
. Further, the difference in 
MIC noted in 8b and 8f (Table II) clearly indicated 
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that the Bacillus subtilis strain is quite susceptible 
compared to Klebsiella pneumonia strain. These can be 
associated with the presence of the peptidoglycan  
cell wall which makes it exhibit a varied mode of 
susceptibility
26
. 
 
Antioxidant activity 
In the present study, the newly synthesized 
compounds were screened for their antioxidant 
properties using metal chelating assay as well as DPPH 
assay at different concentrations and results were 
expressed as a percentage and also in terms of IC50 
(mg/mL). 
The synthesized compounds were screened for 
1,1diphenyl-picrylhydrazyl (DPPH) radical scavenging 
activity having Butylatedhydroxytoluene (BHT)  
as standard and the results have been shown in 
Table III. According to the tabulated data, among the 
synthesized compounds, 8e with chloro substitution at 
para position displayed high degree of radical 
scavenging activity with a lowest IC50 value of 18.976 
mg/mL, followed by the compounds 8b, 8h with 
halogen-substituted (fluoro, bromo) and compound 8a 
with no substitution showed moderate antioxidant 
activity. Furthermore, compound 8c with electron- 
donating methyl group on phenyl ring coupled with 
amide nucleus showed significant oxidative stress- 
reducing activity with IC50 value of 19.564 mg/mL. 
We also observed that compounds 8f, 8g with two 
electron withdrawing groups on phenyl ring drastically 
Table I — Antibacterial activity data of synthesized compounds 8a-h 
Compounds Zone of Inhibition in (mm) 
Gram positive Gram Negative 
Bacillus subtilis Klebsiellapneumoniae 
8a 2.0±0.707 2.4±0.707 0.8±0.141 1.4±0.353 
8b 4.4±0.565 5±0.622 6.5±0.141 8±0.848 
8c 2.0±0.282 2.5±0.424 1.0±0.212 1.5±0.424 
8d 1.9±0.565 2.4±0.282 0.6±0.212 1.25±0.141 
8e 6.8±1.41 8±1.241 7.5±0.424 9±1.55 
8f 4.5±0.565 5.5±0.848 4±0.282 12.5±0.707 
8g 2.3±0.282 2.7±0.424 6±0.565 2.0±0.424 
8h 7.2±0.424 8.5±0.707 8.0±1.55 9.5±0.424 
+ control- Tetracycline 
(std) 
22.5±0.35 - 24±0.70 - 
Zone of inhibition is expressed in millimetres Values are averages ± standard deviations calculated from the data of two independent 
measurements at two different concentration (10 and 20 mg/mL). 
 
Table II — MICs of synthesized compounds 8a-h 
MICs of synthesized compounds (mg/mL) 
Organisms 8a 8b 8c 8d 8e 8f 8g 8h std 
K. pneumonia 1.25 0.312 0.625 1.25 0.156 0.312 0.625 0.078 0.0097 
Bacillus subtilis 1.25 0.156 0.625 1.25 0.078 0.312 0.625 0.078 0.0097 
Std: Tetracycline 
 
Table III — DPPH radical activity results of the compounds 8a-h 
Concentration (mg/mL) Percentage inhibition (%) IC50(mg/mL) 
10 20 30  
Std/Galic acid 60.32± 86.14± 93.71± 18.144 
8a 36.71±1.852 42.51±4.44 49.60±2.420 20.333 
8b 15.23±0.31 029.41±1.00 40.05±3.21 019.564 
8c 15.86±2.680 33.14±1.923 45.20±1.555 19.413 
8d 9.32±1.930 20.59±2.715 42.15±1.555 21.718 
8e 14.76±3.097 34.05±1.371 44.13±4.454 18.976 
8f 32.19±3.691 35.61±2.192 47.40±2.262 21.914 
8g 8.20±1.994 16.55±2.064 34.62±3.620 21.273 
8h 23.11±1.060 30.71±3.973 42.15±2.220 20.665 
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reduced the activity with a higher concentration of 
21.91 and 21.27 mg/mL respectively. 
The chelating capacity of test compounds with Fe+2 
ion varies significantly on the basis of substitution on the 
aromatic ring. The chelating ability of the synthesized 
compounds with ferrous ion is represented in Table IV. 
The results obtained from this method revealed that 
the compound 8a without any substitution as well as 
8h with bromo substitution on aryl group showed the 
highest activity with IC50 values 18.521, 18.740 
mg/mL respectivelywhereas moderate scavenging 
capacity was exhibited by the same compounds in 
DPPH method. The compounds 8d, 8c, 8e, 8f, and 8g 
showed significant chelating capacity with ferrous ion 
compared to EDTA with lower concentration. Though 
the compound 8b, which exhibited moderate free 
radical scavenging activity showed lower chelating 
capability with ferrous ion compared to standard 
(EDTA). 
From both the assays results, it is revealed that the 
compounds showed a varying degree of oxidative 
stress reducing capacity. The compounds which 
showed moderate radical scavenging activity have 
shown least metal chelation capacity and compounds 
with moderate radical scavenging capacity presented 
good ferrous ion chelation property. 
 
Molecular Docking studies 
The enzyme GlcN-6-P synthase leads to the 
formation of UDP-N-acetyl-glucosamine which is the 
major intermediate in the biosynthesis of all amino 
sugars containing macromolecules both in prokaryotic 
and eukaryotic cells. This concerns also the cell  
walls macromolecules. The Peroxisome proliferator-
activ              α (PP Rα),            -activated 
transcription factor and member of the superfamily of 
nuclear hormone receptor. This receptor plays key 
roles in maintaining glucose and lipid homeostasis  
by modulating gene expression of hepatocytes. 
Transforming growth factor beta (TGF-β)             
potent pro-fibrogenic cytokine and its expression is 
increased in almost all of fibrotic diseases. TGF-β1 
increases ROS production and suppresses antioxidant 
enzymes, leading to a redox imbalance. ROS, in turn, 
induce/activate TGF-β1                      GF-β'  
fibrogenic effects, forming a vicious cycle. Hence 
inhibition of these proteins has important implications 
for chemotherapy
27-29
. 
The results of docking assess the quality and 
energy of binding of the structures with the molecules 
of a bio target. The consensus function allows us to 
create a rating of compounds and analyze the data 
regarding the choice of potential agonists/antagonists 
of the biological target selected. The results obtained 
were compared with the known antibiotic, Streptomycin 
and presented in Table V and Figure 1. 
Based on the results of docking studies, it was 
observed that all the synthesized ligand molecules 
showed higher binding energy and the least number of 
hydrogen bonding with protein molecule than 
compared to standard. Among the tested ligands, the 
molecules 8c, 8d, and 8e showed good binding interaction 
(−8.0, −7.8 and −7.8 kcal/mol) and establishes three 
hydrogen bonding with the amino acid molecules in 
relation to the GlcN-6-P synthase protein. Compound 
8g was found to have a least binding interaction  
(−4.2 kcal/mol) and establishes one hydrogen bonding 
with the binding receptor. 
The results obtained were compared with the 
known antioxidant, Silymarine and presented in 
Table VI, Figure 2 and Figure 3. 
The docking of synthesized ligand molecules with 
        PP Rα      GF-β1                     
interaction and hydrogen bonding formed between 
ligand and protein molecules were comparable with 
the standard. Compound 8f showed the highest 
binding interaction (-10.8 kcal/mol) and five 
hydrogen bonding with different amino acids of 
Table IV — Metal chelating results of the compounds 8a-h 
Concentration (mg/mL) Percentage inhibition (%) IC50(mg/mL) 
10 20 30  
Std/EDTA 66.26±4.553 76.17±2.121 96.40±3.606 20.995 
8a 38.19±2.80 59.39±3.408 67.73±2.347 18.521 
8b 19.87±3.63 23.15±4.087 32.16±1.569 22.778 
8c 11.55±3.224 15.88±1.866 20.90±3.153 20.271 
8d 23.12±1.527 27.83±2.729 32.06±2.941 19.844 
8e 7.14±1.654 15.98±2.729 28.04±0.848 20.460 
8f 0.60±0.367 10.75±2.559 25.32±0.947 20.542 
8g 14.02±0.735 18.78±2.390 25.48±2.094 20.657 
8h 22.11±2.022 48.64±3.733 61.40±1.640 18.740 
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PP Rα                               8c 
establishes three hydrogen binding with Ser241 and 
Agr240 amino acid in the active site of target protein 
TGF-β1                               -7.3 kcal/mol. 
Other ligand molecules showed good interaction and 
hydrogen bonding with the target receptor.  
Overall it is predicted that, since the test 
synthesized compounds have a significant  
binding affinity, hydrogen boding and hydrophobic 
interactions with target proteins, the inhibition 
efficiency of the compounds   8(a-h) (Table VII) is 
comparatively higher. 
Table V — Binding energy, H- Bonds, H- Bond length, H-Bond with and hydrophobic interactions of ligands with receptors 
Ligands Target Protein Affinity (kcal/mol) H-bonds H-bond length (Å) H-bond with Hydrophobic 
interactions 
Streptomycin GlcN-6-P synthase - 3.7 10 
2.80 
2.52 
2.99 
2.80, 2.83 
2.65 
2.79 
2.79 
3.11 
Ala 602 
Thr352 
Ser349 
Ser303 
Leu346 
Cys300 
Thr302 
Glu488 
Leu601,Val399, Lys603, 
Ala400, Ser604, Ser347, 
Ala299, Ser401, 
Gly301, Asp354, 
Val605 
8a  - 7.6 3 
2.80, 3.25 
3.07 
Ser303 
Cys300 
Ala400, Val399, Ser405, 
Ala602, Glu488, 
Lys603, Val605, 
Asp354, Thr352, 
Ser604, Thr302 
8b  - 7.2 1 3.28 Lys603 
Ala400, Ala602, val399, 
Gly301, Thr352, 
Val605, Asp354, 
Cys300, Ser347, 
Glu348, Ser303, Ser349 
8c  - 8.0 3 
3.18 
3.23, 3.13 
Gln348 
Cys300 
Lys603, Thr352, 
Glu488, Thr302, 
Val399, Ala602, 
Val605, Asp354, 
Gly301, Ser604, Ser303 
8d  - 7.8 3 
3.14, 3.19 
3.11 
Gln348, Cys300 
Thr352, Gly301, 
Lys603, Glu488, 
Ala602, Leu601, 
Thr302, Val399, 
Asp354, Val605, 
Ser604, Ser303 
8e  - 7.8 3 
3.17, 3.5 
3.09 
Gln348 
Cys300 
Ala602, Lys603, 
Val399, Gly301, 
Glu488, Val605, 
Asp354, Thr302, 
Ser604, Thr352, Ser303 
8f  - 7.6 1 3.7 Thr302 
Lys603, Ser303, 
Gln348, Ser349, Ser604, 
Gly301, Thr352, 
Asp354, Val605, 
Cys300, Glu488, Ser401 
8g  - 4.2 1 2.92 Ala602 
Leu601, Glu488, 
Val605, Gly301, 
Asp354, Cys300, 
Ser303, Thr352, Ser347, 
Glu348, Lys603, 
Ala400, Thr302, Val399 
8h  - 5.4 3 
3.29 
2.80 
3.03 
Ser303 
Thr352 
Val605 
Leu601, Ala602, 
Val399, Thr302, Ser401, 
Ser604, Cys300 
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2D Ligplot analysis and docking results showing crystal structure of GlcN-6-P synthase, ligand Streptomycin (Standard drug),  
B, C, D, E, F, G, H, I.: 2D Ligplot analysis and docking results showing crystal structure of GlcN-6-P synthase with the  
ligand 8a, 8b, 8c, 8d, 8e, 8f, 8g and 8h respectively. 
 
Figure 1 — Molecular docking studies with respect to receptor GlcN-6-P synthase 
 
Table VI — Binding energy, H- Bonds, H- Bond length, H-Bond with and hydrophobic interactions of ligands with receptors 
Ligands Target Protein Affinity (kcal/mol) H-bonds H-bond length (Å) H-bond with Hydrophobic interactions 
Silymarin PP Rα - 6.5 3 
3.29 
2.94 
3.13 
Cys275 
Ser280 
Thr283 
Cys276, Met355, Phe318, 
Leu321, Met330, Ile317, 
Met220, Phe218, Glu286, 
Val324, Met320, Ala333, 
Val332,  Thr279, Leu331 
8a  - 10.3 3 
2.80, 2.82 
3.08 
Ser280 
His440 
Val324, Met220, Leu331, 
Thr279, Leu321, Cys276, 
Met355, Gln277, Phe273, 
Leu456, Val444, Leu460, 
Tyr314, Phe318, Ile317, 
Thr283 
8b  - 10.6 3 
2.80, 2.96 
3.11 
Ser280 
His440 
Met220, Val324, Ile317, 
Thr279, Met355, Cys276, 
Leu456, Gln277, Leu460, 
Phe273, Val444, Phe318, 
Tyr314, Leu331, Thr283 
8c  - 10.7 3 
2.80, 2.84 
3.11 
Ser280 
His440 
Leu331, Val324, Lea321, 
Cys276, Thr279, Met355, 
Gln277, Phe273, Val444, 
Leu456, Tyr465, Leu460, 
Phe318, Ile317, Thr283, 
Tyr314, Met220 
8d  - 10.4 4 
2.97 
2.81, 2.98 
3.09 
Thr279 
Ser280 
His440 
Gly335, Val324, Leu331, 
Met355, Phe273, Cys276, 
Leu456, Gln277, Val444, 
Leu460, Tyr314, Phe318, 
Ile317, Thr283, Leu321, 
Met220 
8e  - 10.6 4 
2.94 
3.02, 2.83 
3.10 
Thr279 
Ser280 
His440 
Phe318, Tyr314, Leu460, 
Leu456, Phe273, Val444, 
Gln277, Cys276, Met355, 
Ile317, Val324, Leu331, 
Leu321, Thr283 
8f  - 10.8 5 
2.91, 2.80 
3.12, 2.97 
3.07 
Thr279 
Ser280 
His440 
Val324, Leu321, Met355, 
Cys276, Leu456, Phe273, 
Glu277, Val444, Tyr314, 
Phe318, Leu460, Ile317, 
Thr283, Met220 
(Contd.) 
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Table VI — Binding energy, H- Bonds, H- Bond length, H-Bond with and hydrophobic interactions of ligands with receptors 
Ligands Target Protein Affinity (kcal/mol) H-bonds H-bond length (Å) H-bond with Hydrophobic interactions 
8g  - 10.7 4 
2.85 
2.70, 2.80 
3.04 
Tyr314 
Ser280 
Thr279 
Leu460,Phe318, Ile317, 
Thr283, Val324, Gly335, 
Leu321, Leu331, Met330, 
Val332, Cys276, Phe273, 
Met355, Leu456, Ile354, 
Val444, His440 
8h  - 10.6 5 
2.89 
2.97, 2.86, 3.10 
3.04 
Thr279 
Ser280 
His440 
Cys276, Met355, Gln277, 
Val444, Leu456, Phe273, 
Leu460, Tyr464, Phe318, 
Leu331, Met220, Ile317, 
Val324, Leu321, Tyr314, 
Thr283 
Silymarin TGF-β1 - 6.8 2 
3.17 
3.18 
Arg240 
Ser241 
Glu247, Phe243, Ile367, 
Arg244, Gly353, Leu354, 
Val373, Phe216, Glu238, 
Arg237 
8a  - 7.0 -- -- -- 
Arg332, Leu354, Val373, 
Arg244, Phe243, Arg240, 
Ser241, ile367, Gly353 
8b  - 7.0 -- -- -- 
Arg244, Ile367, Arg332, 
Val373, Gly353, Leu354, 
Ser241, Arg240, Phe243 
8c  - 7.3 3 
3.14 
3.18, 3.17 
Ser241 
Arg240 
Arg244, Glu247, Phe216, 
Gly353, Val373, Arg215, 
Gly374, Leu354 
8d  - 7.1 1 3.13 Gly374 
Phe216, Val373, Arg240, 
Arg244, Phe243, Ile367, 
Glu247, Leu354, Arg215 
8e  - 7.1 2 3.24, 2.92 Arg240 
Glu247, Ile367, Arg332, 
Val373, Leu354, Ser241, 
Arg244 
8f  - 7.2 2 3.13, 3.15 Arg240 
Glu247, Arg244, Ile367, 
Arg332, Val373, Leu354, 
Ser241, Phe243 
8g  - 7.1 1 2.96 Arg240 
Val373, Arg332, Ile367, 
Arg244, Phe243, leu354, 
Arg215, Phe216 
8h  - 7.2 2 3.7, 3.18 Arg240 
Ser241, Gly353, Val373, 
Leu354, Arg332, Phe243, 
Ile367, Arg244, Ile367, 
Glu247 
 
Experimental Section 
All chemicals and solvents were analytical grade 
and purchased from commercial suppliers Sigma-
Aldrich, Spectrochem, India and used without 
purification. Thin-layer chromatography (TLC) 
experiment was performed on Aluminium backed 
silica gel 40 F254 plates to monitor the progress of 
the reaction. Electro thermal apparatus was used to 
record the melting point of synthesized compounds 
and are uncorrected. The FT-IR spectra were  
recorded in KBr pellets using a Shimadzu FT-IR 
spectrophotometer. 
1
H and 
13
C NMR spectra were 
recorded on the Bruker 400 MHz spectrometer. The 
chemical shifts with reference to TMS as an internal 
                         δ (   )                  
constants (J) values are expressed in Hertz (Hz).  
The mass spectra of synthesized compounds were 
recorded using Agilent LC-MS instrument. 
 
Synthesis of ethyl [(2-oxo-2H-1-benzopyran-3-
carbonyl) amino] acetate, 6 
To the stirred solution of 2-oxo-2H-1-benzopyran-
3-carboxylic acid (10g, 52.59 mmol), glycine ethyl 
ester hydrochloride (10.94g, 78.43mmol) and HOBt 
(12g, 78.43mmol) in 140 mL of DMF, N-methyl 
morpholine (13.23g, 130.74mmol) was added drop 
wise and the stirring was continued for 10 min. at the 
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same temperature. To this, 15.03g of EDC.HCl 
(78.43mmol) was added and the resulted reaction 
mixture was stirred for 5-6 hr at RT. Progress of the 
reaction was monitored by TLC and after completion 
of the reaction, whole reaction mixture was quenched 
with 500 mL of ice cold water and stirred for 30 min. 
The precipitate formed was filtered, washed with 
water and dried under vacuum to afford ethyl [(2-oxo-
2H-1-benzopyran-3-carbonyl) amino] acetate (6) as 
off white solid. (88 %). m.p. 171-173°C. Rf =0.39 
(CHCl3-MeOH 9:1); IR (KBr): 1656.70 (C=O), 
1711.80 (C=O), 1735.75 (C=O), 3314.37 cm
−1
 (N-H); 
1
H NMR (400 MHz, DMSO-d6): δ 1.181 (3 ,  ,  
J = 6Hz, ester-CH3), 4.09 (2H, d, J = 5.5 Hz, glycine-
CH2), 4.27 (2H, q, J1 = 5.4 Hz, J2 = 7.4 Hz, ester-CH2) 
7.48-8.87 (5H, Ar-H) 9.03 (1H, s, amide NH); 
13
C NMR (100 MHz, DMSO-d6): δ 14.51 (     -CH3 ), 
41.92 (amide-CH2), 61.01 (ester-CH2), 116.598, 
118.533, 118.826, 125.597, 130.860, 134.772, 148.63, 
154.43 (coumarin C-Ar), 160.73, 161.82 (coumarin –
C=O) and 169.86 (glycine ester-C=O). MS: m/z 
276.03 (M+H). Anal. Calcd for C14H13NO5 (275.25). 
Synthesis of [(2-oxo-2H-1-benzopyran-3-carbonyl) 
amino] acetic acid, 7 
35 mL Sodium hydroxide solution (10%) was 
added to 10 g of ethyl [(2-oxo-2H-1benzopyran-3-
carbonyl) amino] acetate 6 (36.32 mmol), and the 
resulted solution was refluxed at 100°C for about 2hr. 
The reaction mixture turns to a yellowish solution 
during this period. After completion of the reaction 
(checked by TLC), the reaction mass was cooled to 
RT, diluted with 50 mL of ice and acidified with 
hydrochloric acid (6 N) to pH 3 under constant 
stirring for about 30 min. The precipitate obtained 
was collected by filtration, washed with water and 
finally dried under vacuum to afford [(2-oxo-2H-
1benzopyran-3-carbonyl) amino] acetic acid 7 as off 
pale yellow solid (84%). m.p. 247-250°C. Rf 
=0.28(CHCl3-MeOH 9:1); IR (KBr): 1637.17 (C=O), 
1713.32 (C=O), 1757.43 (C=O), 3313.20 (N-H), 
3462.91 cm
−1
 (O-H); 
1
H NMR (400 MHz, DMSO-d6): 
δ 4.08 (2H, d, J = 5.6 Hz, glycine-CH2 ), 7.54-8.93 
(5H, Ar-H), 9.06 (1H, t, J = 5.2 Hz, -NH), 12.80 (1H, 
s, -COOH); 
13
C NMR (100 MHz, DMSO-d6): δ 
 
 
2D Ligplot analysis and docking results showing crystal structure of PP Rα, ligand Silymarin (Standard drug), B, C, D, E, 
F, G, H, I.: 2D Ligplot analysis and docking results showing crystal structure of PP Rα with the ligands 8a, 8b, 8c, 8d, 8e, 
8f, 8g and 8h respectively 
 
Figure 2 — Molecular docking studies with respect             PP Rα. 
 
 
 
2D Ligplot analysis and docking results showing crystal structure of TGF-β1, ligand Silymarin (Standard drug), B, C, D, E, F, G, H, I.: 2D 
Ligplot analysis and docking results showing crystal structure of TGF-β1with the ligands 8a, 8b, 8c, 8d, 8e, 8f, 8g and 8h respectively. 
 
Figure 3 — Molecular docking studies with respect to receptor TGF-β1. 
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41.937 (amide-CH2), 116.590, 118.602, 118.602, 
118.845, 125.597, 130.851, 134.733, 148.538, 154.424 
(coumarin C-Ar), 160.806, 161.595 (coumarin –
C=O), 171.246 (acid –C=O); MS: m/z 246.0018  
(M-H). Anal. Calcd for C12H9NO5 (247.20). 
General procedure for the synthesis of 
substituted N-[2-(benzylamino)-2-oxoethyl]-2-oxo2H-
1- benzopyran-3-carboxamide derivatives, 8a-h 
To the suspension of hypuric acid 7 (1 mmol)  
and substituted aryl amine (1 mmol) in DMF  
(5 mL), N-ethyl diisopropylamine (3 mmol) was 
added drop wise at 0°C and followed by the  
addition of HATU (1.3 mmol) during a period of  
15 min. The reaction medium was allowed to  
reach RT and stirred for 4 hrs at the same 
temperature. After completion of the reaction, the 
reaction mixture was poured into ice cold water and 
stirred at RT for 30 min. The precipitated solid  
    fi      ,                       k            ng 
under vacuum. 
N-[2-(Benzylamino)-2-oxoethyl]-2-oxo-2H-1-
benzopyran-3-carboxamide, 8a: White solid. m.p. 
200-202°C. IR (KBr): 1654.76 (C=O), 1622.34 (C=O), 
3276.41(N-H), 3327.31 cm
−1
 (N-H); 
1
H NMR (400 
MHz, DMSO-d6): δ 4.23 (2 ,  , J = 3.6 Hz, glycine-
CH2 ), 4.46 (2H, d, J = 4 Hz, benzyl-CH2 ), 7.48-8.87 
(5H, Ar-H), 8.7 (1H, s, amide-NH-benzyl), 8.97 (1H, d, 
J = 6.8Hz, Ar-H), 9.2 (1H, s, amide-NH-glycine); 
13
C NMR (100MHz, DMSO-d6): δ 43.8 (     -CH2), 
43.5(benzyl–CH2), 126.8, 127.3, 128.6, 128.6, 127.1, 
141.7 (Ar-C), 114.1, 121.5, 122.3, 125.5, 126.8, 128.4, 
138.6, 150.3, 159.5, 159.8 (coumarin –C=O), 171.1 
(benzyl amide –C=O); MS: m/z 337.23 (M-H). Anal. 
Calcd for C19H16N2O4 (336.34). 
N-(2-{[(4-Fluorophenyl)methyl]amino}-2-oxoethyl)- 
2-oxo-2H-1-benzopyran-3 carboxamide, 8b: White 
solid, m.p. 208-210°C. IR (KBr): 1100 (C-F), 1658.05 
(C=O), 1716.59 (C=O), 3271.64 (N-H), 3329.31 cm
−1
 
(N-H); 
1
H NMR (100 MHz, DMSO-d6): δ 4.06  
(2H, d, J = 3.6 Hz, glycine-CH2), 4.32 (2H, d, J = 4 
Table VII — Physicochemical data of substituted derivatives 8a-h 
Compd R1 Product MF/M.Wt Yeld(%) m.p. (°C) 
8a NH2
 
O NH
OO
O
NH
 
C19H16N2O4 /336.34 85% 200-202 
8b NH2
F  
O NH
OO
O
NH
F
 
C19H15FNO4 /354.33 87% 208-210 
8c NH2
CH3  
O NH
OO
O
NH
CH3
 
C20H18N2O4 /350.36 88% 228-230 
8d NH2
H3CO  
O NH
OO
O
NH
OCH3
 
C20H18N2O5 /366.36 85% 198-202 
8e NH2
Cl  
O NH
OO
O
NH
Cl
 
C19H15FClN2O4 /370.78 78% 215-216 
8f NH2
Cl
F  
O NH
OO
O
NH
Cl
F
 
C19H14ClFN2O4 /388.77 88% 220-222 
8g NH2
H3CO OCH3  
O NH
OO
O
NH
H3CO OCH3
 
C21H20N2O6/396.39 74% 194-196 
8h NH2
Br  
O NH
OO
O
NH
Br
 
C19H15BrNO4 /415.23 83% 225-227 
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Hz benzyl-CH2 ), 7.18-8.03 (8H, Ar-H), 8.54 (1H, s, 
amide-NH-benzyl), 8.93 (1H, s, ArH), 9.12 (1H, s, 
amide-NH-glycine); 
13
C NMR (100 MHz, DMSO-d6): 
δ 41.84 (     -CH2), 43.24 (benzyl –CH2), 115.28, 
115.49, 116.57, 118.86, 118.98, 125.59, 129.56, 
129.65, 130.79, 134.63, 135.89, 148.14, 154.37, 
160.40, 160.77, 161.57 (coumarin –C=O), 162.82 
(Ar–C-F) 168.65 (benzyl amide –C=O); MS: m/z 
355.02 (M+H). Anal. Calcd for C19H15FNO4 (354.33). 
N-(2-{[(4-Methylphenyl)methyl]amino}-2-
oxoethyl)- 2-oxo-2H-1-benzopyran-3-carboxamide, 
8c: White solid, m.p. 228-230°C. IR (KBr): 1658.60 
(C=O), 1718.99 (C=O), 3332.91 cm
−1
 (NH); 
1
H NMR 
(400 MHz, DMSO-d6): δ 2.24 (3 ,  ,   -CH3), 4.01 
(2H, d, J = 4.4 Hz glycine-CH2), 4.23 (2H, d, J = 5.2 
Hz, benzyl-CH2), 7.13-7.98 (8H, Ar-H), 8.44 (1H, s, 
amideNH-benzyl), 8.88 (1H, s, Ar-H), 9.07 (1H, s, 
amide-NH-glycine); 
13
C NMR (100 MHz, DMSO-d6): δ 
25.63 (Ar-CH3), 41.84 (amide-CH2), 43.24 (benzyl –
CH2), 115.28, 115.49, 116.57, 118.86, 118.98, 125.59, 
129.566, 129.65, 130.79, 134.63, 135.89, 148.14, 154.37 
(coumarin C-Ar), 160.77, 161.57 51 (coumarin –C=O), 
168.82 (benzyl amide –C=O); LCMS: m/z 335.04 (M-
H). Anal. Calcd for C20H18N2O4 (350.36). 
N-(2-{[(4-Methoxyphenyl)methyl]amino}-2-
oxoethyl)-2-oxo-2H-1-benzopyran-3carboxamide, 
8d: White solid, m.p. 198-202°C. IR (KBr): 1611.20 
(C=O), 1657 (C=O), 1720.74 (C=O), 3279.33 (N-H), 
3340.74 cm
−1
 (N-H); 
1
H NMR (400 MHz, DMSO-d6): 
δ 3.73 (3 ,  ,   -OCH3), 4.24 (2H, d, J = 4.8Hz, 
glycine-CH2), 4.26 (2H, d, J = 4.6 Hz, benzyl-CH2), 
6.94-8.03 (8H, Ar-H), 8.49 (1H, t, J = 12Hz, amide-
NH-benzyl), 8.93 (1H, s, Ar-H), 9.13 (1H, t,  
J = 5.2Hz, amide-NH-glycine); 
13
C NMR (100 MHz, 
DMSO-d6): δ 42.02 (     -CH2), 43.22 (benzyl –CH2), 
55.50 (Ar-OCH3), 114.12, 116.57, 118.87, 118.98, 
125.59, 129.03, 130.78, 131.57, 134.63, 148.12, 
154.37, 158.68, 160.77, 161.51 (coumarin –C=O), 
168.41 (benzyl amide –C=O), MS: m/z 367.04 
(M+H). Anal. Calcd for C20H18N2O5 (366.36). 
N-(2-{[(2-Chlorophenyl)methyl]amino}-2-
oxoethyl)-2-oxo-2H-1-benzopyran-3-carboxamide, 
8e: White solid. m.p. 215-216°C. IR (KBr): 781.23 
(C-Cl), 1608.62 (C=O), 1658.05 (C=O), 1716.59 
(C=O), 3271.64 (N-H), 3329.31 cm
−1
 (N-H); 
1
H NMR 
(400 MHz, DMSO-d6): δ 4.06 (2 ,  , J = 3.6 Hz, 
glycine-CH2), 4.32 (2H, d, J = 4 Hz, benzyl-CH2 ), 
7.18-8.03 (8H, Ar-H), 8.54 (1H, s, amide- 
NH-benzyl), 8.93 (1H, s, Ar-H), 9.12 (1H, s, amide-
NH-glycine); 
13
C NMR (100 MHz, DMSO-d6): δ 
41.84 (amide-CH2), 43.24 (benzyl –CH2), 115.284, 
115.498, 116.578, 118.865, 118.985, 125.597, 128.82 
(Ar–C-Cl), 129.566, 129.654, 130.792, 134.635, 
135.8900, 148.149, 154.376, 160.40, 160.77, 161.57 
(coumarin –C=O), 168.658 (benzyl amide –C=O); 
HRMS: m/z 371.28 (M+H). Anal. Calcd for C20H18N2O5  
(370.78). 
N-(2-{[(2-Chloro-3-fluorophenyl) methyl] amino}- 
2-oxoethyl)-2-oxo-2H-1-benzopyran-3-carboxamide, 
8f: White solid. m.p. 220-222°C. IR (KBr): 783.21 (C-
Cl), 1021.34 (C-F), 1655.76 (C=O), 1619.34 (C=O), 
3345.61 cm
−1
 (N-H); 
1
H NMR (400 MHz, DMSO-d6): δ 
4.05 (2H, d, J = 5.2 Hz, glycine-CH2), 4.38 (2H, d, J = 
5.6 Hz, benzyl-CH2), 7.22-8.02 (7H, Ar-H), 8.61 (1H, t, 
J = 6.8Hz, amide-NH-benzyl), 8.92 (1H, s, Ar-H),  
9.11 (1H, t, J = 5.2Hz, amide-NHglycine); 
13
C NMR 
(400MHz, DMSO-d6): δ 35.7 (     -CH2), 42.8 (benzyl 
–CH2), 119.4, 119.4, 124.0, 128.3, 138.6, 144.1 (Ar-C), 
114.2, 120.5, 122.3, 125.4, 126.8, 128.2, 138.5, 150.4, 
159.5, 159.5 (coumarin –C=O), 171.1(benzyl amide –
C=O). LCMS: m/z 389.34 (M+H). Anal. Calcd 
forC19H14 ClFN2O4 (388.77). 
N-(2-{[(2,4-Dimethoxyphenyl)methyl]amino}-2-
oxoethyl)-2-oxo-2H-1-benzopyran-3carboxamide, 
8g: White solid, m.p. 194-196°C. IR (KBr): 1611.20 
(C-O), 1657 (C=O), 1720.74 (C=O), 3279.33 (N-H), 
3340.74 cm
−1
 (N-H); 
1
H NMR (400 MHz, DMSO-d6): 
δ 3.73 (3 ,  ,   -OCH3), 3.73 (3H, s, Ar- OCH3), 
4.2(2H, d, J = 4.8 Hz, glycine-CH2), 4.26 (2H, d,  
J = 4.6 Hz, benzyl-CH2), 7.18-8.03 (8H, Ar-H), 8.49  
(1H, t, J = 12Hz, amide-NH-benzyl), 8.93 (1H, s,  
Ar-H), 9.13 (1H, t, J = 5.2Hz, amide-NH-glycine); 
13
C NMR (100 MHz, DMSO-d6): δ 42.02 (     -
CH2), 43.22 (benzyl –CH2), 55.50 (Ar-OCH3), 55.51 
(Ar-OCH3),114.12, 116.57, 118.87, 118.98, 125.59, 
129.03, 130.78, 131.57, 134.63, 148.12, 154.37, 
158.68, 160.77, 161.51 (coumarin – C=O), 168.41 
(benzyl amide –C=O); HRMS: m/z 397.24 (M+H). 
Anal. Calcd for C20H18N2O5 (396.39). 
N-(2-{[(4-Bromophenyl)methyl]amino}-2-oxoethyl)- 
2-oxo-2H-1-benzopyran-3-carboxamide, 8h: White 
solid. m.p. 194-196°C. IR (KBr): 1611.20 (C-O), 
1657 (C=O), 1720.74 (C=O), 3279.33 (N-H), 3340.74 
cm
−1
 (N-H); 
1
H NMR (400 MHz, DMSO-d6): δ 3.73 
(3H, s, Ar-OCH3), 3.73 (3H, s, Ar- OCH3), 4.2 (2H, d, 
J = 4.8 Hz, glycine-CH2), 4.26 (2H, d,  
J = 4.6 Hz, benzyl-CH2), 6 7.32-8.03 (8H, Ar-H), 8.49 
(1H, t, J = 12Hz, amide-NH-benzyl), 8.93 (1H, s,  
Ar-H), 9.13(1H, t, J = 5.2Hz, amide-NH-glycine); 
13
C NMR (100 MHz, DMSO-d6): δ 42.02 (     -
CH2), 43.22 (benzyl –CH2), 55.50 (Ar-OCH3), 55.51 
(Ar-OCH3), 114.12, 116.57, 118.87, 118.98, 125.59, 
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129.03, 130.78, 131.57, 134.63, 148.12, 154.37, 
158.68, 160.77, 161.51 (coumarin – C=O), 168.41 
(benzyl amide –C=O), HRMS: m/z 397.24 (M+H). 
Anal. Calcd for C20H18N2O5 (396.39). 
 
Antibacterial activity 
The antibacterial activities of the synthesized 
compounds were performed by the agar well diffusion 
method as previously described
30
. Nutrient agar was 
poured on the Petri dish and allowed to solidify. 
Overnight grown bacterial strains (Klebsiella 
pneumonia, and Bacillus subtilis) were seeded on to 
Petri dish plates and wells of 6.0-mm diameter were 
                      50 μL                z   
compounds 8(a-h) were added to the wells. Petri dish 
plates were kept for incubation for 24 hr at 37°C. The 
resulting zone of inhibition flanging the wells was 
measured in millimetre (mm) and used as criterion for 
the antibacterial activity. DMSO was used as a 
negative control while tetracycline as standard.  
 
Absorbance based Microtitre Plate Assay (MPA) 
Microtitre plate assay was performed as previously 
described
31-33
                         . 100 μL    
sterile nutrient broth media was pipette into wells of 
the 96-                . S    q      , 100 μL    q    
of synthesized compounds of stock concentration 
10mg/mL were added and then serially diluted in each 
well. Aft                  , 100 μL                    
culture of Klebsiella pneumonia and Bacillus subtilis 
media of 0.4 OD at 600 nm was added into all wells. 
Positive control used contain sterile growth media and 
grown bacterial strains whereas the negative control 
contains synthesized compounds and sterile growth 
media only. The absorbance was recorded by using 
EnSpire Multimode PlateReader using 96-well plate 
at 600 nm before incubation and after incubation  
at 37°C for 24 hr. The MIC value for the synthesized 
compounds was expressed as the lowest concentration 
that inhibits bacterial growth. All tests were 
performed in duplicate. 
 
Antioxidants activity 
 
DPPH scavenging activity 
Radical scavenging activity was determined 
according to Blois
34
 with some modification. An 
aliquot of 25 µL with different concentrations of 10, 
20, 30 mg/mL of synthesized compounds dissolved in 
DMSO was put in a microplate and mixed with  
175 µL (0.5 mM) of ethanolic solution of DPPH.  
The mixture was incubated at room for 30 minutes. 
The gallic acid was used as the standard. The 
decolourization of DPPH solution was determined by 
measuring the absorbance at 517 nm using EnSpire 
Multimode Plate Reader against blank containing 
only DPPH. The percentage inhibition activity was 
calculated using the formula given below and IC50 
(Inhibitory concentration) was displayed in Table IV. 
% inhibition of DPPH radical= [(Abr-Aar)/ Abr× 
100]. Where Abr is the absorbance before reaction 
and Aar is the absorbance after the reaction has taken 
place. All the experiments were performed in 
duplicate and average were calculated.  
Metal Chelating assay The Fe (II) binding ability  
of the chelators was determined according to the 
method of Dinis
35
 with some modification according 
to Adjimani
36 
by substituting ferrous chloride by 
ferrous sulphate. Ferrozine can quantitatively  
form complexes with ferrous iron yielding a red 
colour. However, in the presence of chelating  
agents, there is a disruption of the formation of the 
complex which leads to a decrease in the red color. 
Measurement of colour reduction gives an estimation 
of the binding ability of the coexisting chelator.  
An aliquot of 25 µL with different concentrations  
of 10, 20, 30 mg/mL of synthesized compounds 
dissolved in DMSO was mixed with 0.125 µL of  
0.2 mM ferrous sulphate in a microplate. The reaction 
is started by the addition of 50 µL of 5 mMferrozine, 
mixed properly and incubated at RT for 10 min.  
The ferrous ion was monitored by measuring the 
formation of a red ferrous ion-ferrozine complex at 
562 nm. The percentage inhibition activity was 
calculated by the formula: % Inhibition of metal 
chelating activity= [(Ac-As)/ Ac× 100]. 
Where Ac is the absorbance of control  
before reaction and As is the absorbance of iron 
chelator. IC50 (Inhibitory concentration) was also 
determined and represented in Table V. All the 
experiments were performed in replicate and average 
were calculated. 
 
Molecular Docking studies 
The structure of the target glucosamine-6-
phosphate synthase (GlcN-6-p synthase), Peroxisome 
Proliferator-    v     R              (PP Rα)     
                           β1 ( GF-β1),     
obtained from Protein Data Bank (PDB ID; 2VF5, 
5HYK, and 1VJY). Structures of synthesized 
compounds 8(a-h) were drawn and analyzed using 
ChemDraw Ultra 12.0. 3D coordinates were obtained 
using PRODRG online server
37
. Active pockets  
for proteins were obtained from CASTpserver
38
. 
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Intermediary steps, such as energy minimization, 
protein and ligands preparation and grid box creation 
were completed using Graphical User Interface 
program AutoDock Tools (ADT). AutoDock/Vina 
employs iterated local search global optimizer
39,40
. 
During the docking procedure, both the protein and 
ligands are considered as rigid. The results less than 
1.0 Ao in positional root-mean-square deviation (RMSD) 
was clustered together and represented by the result 
with the most favourable free energy of binding. The 
pose with lowest energy of binding or binding affinity 
was extracted and aligned with receptor structure for 
further analysis
41,42
. 
 
Conclusion 
We have designed and synthesized a novel series of 
2-(benzylamino)-2-oxoethyl]-2-oxo-2H-1-benzopyran-3 
-carboxamide derivatives using acid amine coupling 
reaction with suitable coupling reagents. All the 
synthesized compounds were characterized by IR, 
1
H NMR, 
13
C NMR, and mass spectrometry analysis. 
Further, synthesized compounds were screened  
for their anti-bacterial and anti-oxidant activity.  
Out of eight derivatives, compounds 8c, 8e, and 8a, 
8h exhibited efficient anti-oxidant activity in DPPH 
and metal ion chelating assay. On the other hand 
inhibition efficacy of synthesized compounds against 
the test pathogens showed moderate activity. 
 
Acknowledgments 
The authors thank the Chairman, Department of 
Industrial Chemistry, Kuvempu University, Shankaraghatta 
for providing laboratory facilities. 
 
Conflict of Interest 
There are no conflict of interest. 
 
References 
1 Melagraki G, Antreas A, Igglessi-Markopoulou O, Anastasia D, 
Maria K, Christos K & Dimitra J H L, Eur J Med Chem, 44 
(2009) 3020. 
2 Kallappa M H, Dinesh S R & Hirihalli C D, RSC Adv, 5 
(2015) 11261. 
3 Moustafa A G, Moged A B, Eman A B & Wafaa S H, Med 
Chem Res, 21 (2012) 1062. 
4 Suresh K, Veeresh M, Prashan T A, Mahesh P, Pradeep K R, 
Shivalingarao M, Thippeswamy A H M & Satyanarayana D, 
Eur J Med Chem, 44 (2009) 1682. 
5 Selvam P, Ramlakshmi I N, Uma G, Arun Kumar S & 
Umamaheswari A, Rasayan J Chem, 3 (2010) 275. 
6 Dinker I B, Niraj H P, Anil K P, Mehul A P & Varun G P,  
J Heterocycl Chem, 48 (2011) 840. 
7          -R      ,       M  ,     k K S,     S fi   K A & 
Mubarak M S, Med Chem Res, 21 (2012) 468. 
8 Sankappa U R, Arun M I, Prakash S, Vijesh A M, Nithin P, 
Shrikrishna I, Thiageeswaran M & Fun H-K, Eur J Med 
Chem, 45 (2010) 2695. 
9 Bahubali M C, Samundeeswari S, Megharaja H, Lokesh A S, 
Sunee I D, Sunil J, Sheshagiri R D, Shrinivas D J & Vinay A 
S, Eur J Med Chem, 125 (2017) 101. 
10 Varun G B, Chirag V P, Niraj H P & Dinkar I B, Med Chem 
Res, 22 (2013) 4338. 
11 Augustine J K, Agnes B, Balakrishna R & Chandrakantha B, 
Tetrahedron Lett, 53 (2012) 4422. 
12 Majumdar K C, Srikanta S, Ansarya I & Roya B, RSC Adv, 2 
(2012) 2137. 
13 Nojoon M, Stephen C, Boyoung K, Sungb J P, Ian A, 
Wilson, Jeffery W K & Sungwook C, Chem Commun, 49 
(2013) 9188. 
14 He X, Shang Y, Zhou Y, Zhiyu Y, Guang H, Wenjing J & 
Jiaojiao C, Tetrahedron, 71 (2014) 863. 
15 Saba K J S, Madivalagouda S S, Mahadev N K, Praveen K 
B, Ravindra R K, Sanjeev R I & Shrinivas D, J Chem Select, 
3 (2018) 4448. 
16 Bakr Abdel-Wahab F, Hanan A M & Abdelbasset A F,  
Org Commun, 7 (2014) 1. 
17 Giorgia G, Andrew J H & Vladimir G, Talanta, 188 (2018) 
448. 
18 Zhang M-Z, Zhang R-R, Yin W-Z, Yu X, Zhang Y-L, Liu P, 
Gu Y-C & Zhang W-H, Mol Divers, 20 (2016) 611. 
19 Shenghong K, Baoan S, Jian W, Ming H, Deyu H, Linhong 
J, Song Z & Wei X Y, Eur J Med Chem, 67 (2013) 14. 
20 Ghanei-Nasab S, Khoobi M, Hadizadeh F, Marjani A, 
Moradi A, Nadri H, Emam S, Foroumadi A & Shafiee A, 
Eur J Med Chem, 121 (2016) 40. 
21 Bouckaert C, Silvia S, Rondelet G, Eduard D, Johan W, 
Jean-Michel D, Raphaël F & Lionel P, Eur J Med Chem, 110 
(2016) 181. 
22 Liu H, Ren Z-L, Wang W, Gong J-X, Chu M-J, Ma Q-W, 
Wang J-C & Lv X-H, Eur J Med Chem, 157 (2018) 81. 
23 Franco C, Bruna B, Adriana B, Daniela S, Paola C, Arianna 
G, Simone C, Daniela R, Alessandra Z, Maddalena S M & 
Francesca S, Bioorg Med Chem Lett, 20 (2010) 4922. 
24 Rama Ganesh C K, Yadav D B & Venkatesh K B, Indian J 
Chem, 49 (2010) 1151. 
25 Sharma P, Rane N & Gurram V K, Bioorg Med Chem Lett, 
14 (2004) 4185. 
26 Tenover F C, Am J Med, 119 (2006) S3-S10. 
27 Malek S, Huang D B, Huxford T, Ghosh S & Ghosh G,  
J Biol Chem, 278 (2003) 23094. 
28 Rigano D, Sirignano C & Taglialatela-Scafati O, Acta Pharm 
Sini B, 7 (2017) 427. 
29 Liu R M & Desai L P, Redox Biol, 6 (2015)565. 
30 Wayne P A, Clinical and Laboratory Standards Institute 
CLSI M7-A7 (2006). 
31 Schelz Z, Molnar J & Hohmann J, Fitoterapia, 77 (2006) 
279. 
32 Gutierrez J, Barry-Ryan C & Bourke P, Food Microbiol, 26 
(2009) 142. 
33 Devienne K F & Raddi M S G, Brazilian J Microbiol, 33 
(2002) 166. 
34 Blois M S, Nature, 181 (1958) 1199. 
35 Dinis T C P, Maderia V M & Almeid L M, Arch Biochem 
Biophys, 315 (1994) 161. 
36 Adjimani J P & Asare P, Toxicology Reports, 2 (2015) 721. 
NAIK et al.: NOVEL BENZOPYRAN-3-CARBOXAMIDE DERIVATIVES 
 
 
419 
37 Schüttelkopf A W & van Aalten D M F, Acta Crystallogr, 60 
(2004) 1355. 
38 Tian W, Chen C, Lei X, Zhao J & Liang J, Nucleic Acids 
Res, 46 (2018) 363. 
39 Morris G M, Huey R, Lindstrom W, Sanner M F,  
Belew R K, Goodsell D S & Olson A J, J Comput Chem,16 
(2009) 2785. 
40 Trott O &Olson A J, J Comput Chem, 31 (2010) 455. 
41 Sudhesh L S, Krishna V, Ravi Kumar S, Santosh Kumar S R, 
Venkatesh R & Pradeepa K, World J Pharm Sci, 4 (2016) 
331. 
42 Venkatesh, Krishna V, Jayabaskaran C, Pradeepa K,  
Sudhesh L S & Lingaraju G M K, Int J Fundamental Appl 
Sci, 7 (2018) 2. 
 
 
